Tarn Biosciences Inc Profile last edited on: 2/3/2024
CAGE: 84YC9
UEI: NNLCRS28GLL8
Business Identifier: Developing therapies for infectious diseases with a focus on treatments of tuberculosis (TB), nontuberculous mycobacterial (NTM) and other mycobacterial infections 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
325 E Grand River Avenue Rm 316
East Lansing, MI 48823
East Lansing, MI 48823
| (517) 203-9647 |
| info@tarnbio.com |
| www.tarnbio.com |
Location: Single
Congr. District: 07
County: Ingham
Congr. District: 07
County: Ingham
Public Profile
Tarn Biosciences Inc is an operator of a biotech organization intended to develop therapies for infectious diseases. The company focuses on treatments of tuberculosis, nontuberculous mycobacterial and other mycobacterial infections, offering both oral and inhaled drugs, enabling patients with improved safety and dosing frequencies where drug therapies fall short and effective treatments for those species have no effective treatments.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2024 | 2 | NIH | $590,374 | |
| Project Title: Development of the HC2099 series of MmpL3 inhibitors to treat tuberculosis | ||||
Key People / Management
John James Vrbanac -- Chief Executive Officer
Robert Abramovitch -- Founder & Chief Scientific Officer
Edmund Ellsworth -- Chief Technology Officer
Robert Abramovitch -- Founder & Chief Scientific Officer
Edmund Ellsworth -- Chief Technology Officer
Company News
There are no news available.
